EUCTR2008-001876-67-Outside-EU/EEA进行中（未招募）1 期
A 6-Month Open-Label, Multicenter, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Children and Adolescent Outpatients With Major Depressive Disorder.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 283
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 - Completed study B2061032 and who in the investigator’s opinion, would benefit from long term treatment with DVS SR
- •2 - Willingness and ability to comply with scheduled visits, treatment plan, and procedures
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 283
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 - Requires precaution against suicide
- •2 - Not generally healthy medical condition
- •3 - Poor compliance with study drug or study procedures during participation in study B2061032
研究者
相似试验
进行中（未招募）
不适用
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Children And Adolescent Outpatients With Major Depressive DisorderMajor Depressive DisorderEUCTR2008-002064-34-Outside-EU/EEAPfizer Inc.269
进行中（未招募）
不适用
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive DisorderMajor Depressive DisorderEUCTR2008-002067-14-Outside-EU/EEAWyeth Research40
已完成
3 期
Flexible Dose, Long-term Safety Study of Asenapine for the Treatmentof Schizophrenia in Adolescents (P05897 AM1) (ADDRESS-97)Schizophrenia, DisorganizedSchizophrenia, UndifferentiatedHealth Condition 2: F209- Schizophrenia, unspecifiedCTRI/2012/02/002403Merck Sharp and Dohme Corp150
进行中（未招募）
1 期
A 26-week, multi-center, open-label, flexible dose, long-term safety trial of asenapine in adolescent subjects with schizophrenia - Gemini-S26SchizophreniaEUCTR2009-018038-12-ROSchering-Plough Research Institute, a Division of Schering Corporation204
进行中（未招募）
不适用
urasidone extension study for the treatment of schizophrenia in paediatric patientsSchizophreniaEUCTR2013-001694-24-Outside-EU/EEASunovion Pharmaceuticals Inc.295